前叶撕裂术预防经导管二尖瓣置换术中左室流出道梗阻
这项前瞻性多中心试验研究LAMPOON联合经房间隔TMVR在瓣环成形环或二尖瓣环钙化患者中的效果。30例高或极高外科风险且TMVR有LVOT梗阻禁忌的患者入组,LAMPOON成功率为100%,手术生存率100%,30天生存率93%,主要成功率为73%,无卒中。LAMPOON可行且安全,能有效预防TMVR导致的LVOT梗阻,但Sapien 3在瓣环成形环和MAC中仍存在重要局限。
要点
- LAMPOON在原生瓣环和瓣环成形环解剖中均可行,手术生存率100%。
- 主要成功率为73%,受瓣周漏额外手术和高裙边neo-LVOT梯度影响。
- 30天生存率93%,无卒中,安全性可接受。
核心结论
- LAMPOON在原生和瓣环成形环解剖中可行且安全,能有效预防TMVR导致的LVOT梗阻。
- 尽管联合LAMPOON,Sapien 3在瓣环成形环和MAC中仍表现出重要局限。
研究设计与样本
- 前瞻性多中心试验,纳入30例高或极高外科风险且TMVR有LVOT梗阻禁忌的患者,均分于MAC组和瓣环成形环组。
- 主要终点为手术生存且LAMPOON成功、TMVR成功、无再干预,且LVOT梯度<30 mm Hg(最佳)或<50 mm Hg(可接受)。
- 次要终点包括30天死亡率和主要不良心血管事件,所有终点独立裁定,中心实验室分析超声和CT图像。
主要发现
- LAMPOON穿越和中线撕裂成功率为100%。
- 手术生存率为100%,30天生存率为93%。
- 主要成功率为73%,原因包括瓣周漏额外手术(10%)和方案修改前观察到的高裙边neo-LVOT梯度。
- 无卒中发生。
关键数值与推荐
- 主要终点定义:手术生存且LAMPOON成功、TMVR成功、无再干预,LVOT梯度<30 mm Hg为最佳或<50 mm Hg为可接受。
- 入组标准:高或极高外科风险且TMVR有LVOT梗阻禁忌;试验中期修改排除Sapien 3瓣膜织物裙边导致LVOT梗阻威胁的受试者。
临床怎么用
- 对于TMVR有LVOT梗阻禁忌的高危患者,LAMPOON可作为预防LVOT梗阻的可行选择。
- 使用Sapien 3在瓣环成形环或MAC中行TMVR时,即使联合LAMPOON仍需警惕瓣周漏和高neo-LVOT梯度等局限。
局限性
- 样本量较小(30例),随访期限主要报告30天结果。
- 试验中期修改了入选标准,可能影响结果解释。
- Sapien 3在瓣环成形环和MAC中的局限提示LAMPOON并非能完全克服所有LVOT梗阻风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left ventricular outflow tract (LVOT) obstruction is a leading cause of mortality and exclusion from transcatheter mitral valve replacement (TMVR). Intentional laceration of the anterior mitral valve leaflet to prevent LVOT obstruction (LAMPOON) is a transcatheter mimic of surgical chord-sparing leaflet resection. OBJECTIVES: The purpose of this prospective multicenter trial was to study LAMPOON with transseptal (Edwards Lifesciences, Irvine, California) TMVR in annuloplasty rings or native mitral annular calcification (MAC). METHODS: Subjects at high or extreme surgical risk and prohibitive risk of LVOT obstruction from TMVR were included. Eligibility was modified midtrial to exclude subjects with threatened LVOT obstruction from a Sapien 3 valve fabric skirt. The primary endpoint was procedure survival with successful LAMPOON, with successful TMVR, without reintervention, and with LVOT gradient <30 mm Hg ("optimal") or <50 mm Hg ("acceptable"). Secondary endpoints included 30-day mortality and major adverse cardiovascular events. There was universal source-data verification and independent monitoring. All endpoints were independently adjudicated. Central laboratories analyzed echocardiogram and CT images. RESULTS: Between June 2017 and June 2018, 30 subjects were enrolled equally between the MAC and ring arms. LAMPOON traversal and midline laceration was successful in 100%. Procedure survival was 100%, and 30-day survival was 93%. Primary success was achieved in 73%, driven by additional procedures for paravalvular leak (10%) and high-skirt neo-LVOT gradients observed before a protocol amendment. There were no strokes. CONCLUSIONS: LAMPOON was feasible in native and annuloplasty ring anatomies in patients who were otherwise ineligible for treatment, with acceptable safety. LAMPOON was effective in preventing LVOT obstruction from TMVR. Despite LAMPOON, TMVR using Sapien 3 in annuloplasty rings and MAC still exhibits important limitations. (NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation; NCT03015194).
引用
- Khan JM, Babaliaros VC, Greenbaum AB, et al. Anterior Leaflet Laceration to Prevent Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Replacement. J Am Coll Cardiol. 2019. PMID: 31118146. doi:10.1016/j.jacc.2019.02.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。